Rubaiul Murshed's scientific contributions

Publications (3)

Article
Full-text available
Domestic Helping Hands are one of the most vulnerable and exploited groups among informal workers in Bangladesh and the world. Considering their vulnerabilities, this cross-sectional study was carried out in Dhaka city to determine the factors associated with the working environment and safety of the Domestic Helping Hands. In this study, a total o...
Article
Full-text available
Introduction: While multiple vaccines are undergoing clinical trial across the globe, we yearn for an FDA approved drug to protect us from the devastating pandemic for the time being. This study aims to determine the effectiveness of Ivermectin when administered as pre-exposure prophylaxis for COVID-19. Method: An observational study, with 118 heal...
Article
Full-text available
Background: A definitive treatment of SARS CoV-2 is yet to arrive and the human death toll rises exponentially globally. In this health emergency, it might be useful to look into the old therapies which could be effective against the virus. In vitro research showed Ivermectin could decrease the concentration of coronavirus 4000 to 5000 folds in liv...

Citations

... Over 40 peer-reviewed studies (Table 1) have demonstrated studies on the effectiveness of IVM in SARS-CoV-2 infection (Alam et al., 2020;Khan et al., 2020;Kishoria et al., 2020;Reaz et al., 2020;Abd-Elsalam et al., 2021;Ahmed et al., 2021;Ahsan et al., 2021;Aref et al., 2021;Behera et al., 2021;Cadegiani et al., 2021;Chaccour et al., 2021;Chahla et al., 2021;Chowdhury et al., 2021;Elalfy et al., 2021;Faisal et al., 2021;Ferreira et al., 2021;Hellwig and Maia, 2021;Krolewiecki et al., 2021;Lima-Morales et al., 2021;López-Medina et al., 2021;Mohan et al., 2021;Morgenstern et al., 2021;Mukarram, 2021;Okumuş et al., 2021;Podder et al., 2021;Rajter et al., 2021;Ravikirti et al., 2021;Rezk et al., 2021;Seet et al., 2021;Shahbaznejad et al., 2021;Shoumann et al., 2021;Abbas et al., 2022;Ascencio-Montiel et al., 2022;Babalola et al., 2022;Beltran Gonzalez et al., 2022;Buonfrate et al., 2022;Hazan et al., 2022a;Kerr et al., 2022;Lim et al., 2022;Mayer et al., 2022;Mustafa et al., 2022;Ozer et al., 2022;Reis et al., 2022;Shimizu et al., 2022;Zubair et al., 2022), with over 80% of studies showing positive outcomes with IVM treatment. Overall, IVM has shown 60-85% improvement in outcomes, including mortality, ventilation, recovery, clearance, and hospital/ICU admissions. ...
... The first three studies were conducted in Bangladesh in the summer of 2020, demonstrating that mild-moderate COVID-19 patients receiving IVM in combination with doxycycline showed a faster negative conversion in PCR and significantly faster symptom resolution compared to the HCQ-AZ-treated group [255]. Moreover, IVM-doxycycline also resulted in a faster viral clearance [256] in severe COVID-19 patients [257], together with improvements in early recovery and prevention to progression to more serious disease [258]. In addition, in a case series of SARS-CoV-2 positive patients hospitalized in Pakistan, IVM combined with doxycycline, remdesivir, tocilizumab, enoxaparin sodium and steroids, emerged as potential new treatment options by reducing the disease-associated severity and recovery rate [259]. ...